ABT Abbott Laboratories

Abbott Laboratories manufactures diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals across global markets. Sector: Healthcare.

Abbott Laboratories (ABT) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On a capital return basis, ROIC is 10.95%, WACC is 8.18%, and the economic spread is 2.77%. On balance, the economic spread is positive but compressed — adequate for value preservation, less convincing for aggressive compounding. Supporting metrics show ROE at 13.00% and ROA at 7.22%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

On an earnings multiple basis, trailing P/E of 27.65, forward P/E of 18.49, PEG of 3.98. The spread between trailing and forward P/E is moderate, suggesting some earnings improvement is expected but not a dramatic re-rating. The PEG ratio is elevated, suggesting investors are paying a premium for the growth embedded in current earnings estimates. A current ratio of 1.58 suggests the the company have sufficient short-term liquidity without excess. Combining multiples and liquidity, the company appears adequately priced for its current earnings trajectory, with balance sheet health providing a degree of downside resilience.

Stripping to unit economics, gross margin sits at 56.54%, operating margin at 19.14%, and free cash flow margin at 16.68%. Gross margins are healthy, suggesting solid pricing power across the company. The operating margin reading is constructive, suggesting management teams are managing overhead costs effectively. At this FCF margin level, the company demonstrate good cash generation relative to the revenue base. Read as a whole, the margin picture suggests a business with strengths in parts but no clear margin dominance end-to-end.

Revenue trends and analyst expectations together suggest: TTM revenue growth of 4.42% indicating muted but still positive top-line momentum across the company, while the estimated 12-month price change of 32.29%, where consensus targets imply substantial appreciation potential over the next 12 months. At 49.5%, the projected 12-month EPS growth rate is strong enough to be a primary driver of the forward investment case rather than a peripheral supporting detail. There is always distance between what is reported and what is priced; the question of whether that distance is closing or widening is what makes the setup interesting. In either direction, the fundamental driver of returns will be whether the company can sustain the trajectory that is already being priced. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Overall, the fundamentals support a constructive stance — execution remains the key driver of whether the forward case is fully validated.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.